Note 10. Share-based Compensation:

During the quarter ended September 30, 2023 and 2022, the Company granted 0.8 million and 2.3 million stock options at weighted average grant prices of $84.34 and $94.43 and weighted average fair values of $28.58 and $29.65, respectively. During the quarter ended September 30, 2023 and 2022, the Company granted 268,961 and 87,852 restricted stock units at a weighted average fair value of $84.44 and $94.38, respectively. During the quarter ended September 30, 2023 and 2022, the Company did not grant restricted common stock shares.

Stock options for 1,027,777 and 660,120 shares of common stock with total intrinsic values of $54.3 million and $41.1 million were exercised during the quarter ended September 30, 2023 and 2022, respectively.

Stock-based compensation expense, inclusive of payroll taxes, of $11.1 million and $15.1 million was included in selling, general and administrative expenses for the quarter ended September 30, 2023 and 2022 respectively. Additionally, the company recognized $0.2 million of stock-based compensation costs in cost of goods sold during the quarter ended September 30, 2023 compared to $0.3 million in the comparative prior year period. As of September 30, 2023, there was $68.6 million of unrecognized compensation cost related to non-vested stock options, non-vested restricted stock units and non-vested restricted stock. The weighted average period over which the compensation cost is expected to be recognized is 2.1 years.

In fiscal 2015, the Company established the Bio-Techne Corporation 2014 Employee Stock Purchase Plan (ESPP), which was approved by the Company's shareholders on October 30, 2014, and which is designed to comply with IRS provisions governing employee stock purchase plans. 800,000 shares were allocated to the ESPP. For ESPP, the Company recorded stock-based compensation expense of $0.1 million for the quarter ended September 30, 2023 and $0.1 million for the quarter ended September 30, 2022.